Arno Therapeutics', AR12 and AR42 were treatment consideration for NF2. Following Phase 0 mice trials, AR42 was determined to be more likely to be effective. AR12 did not go further in clinical trials.
||AR12, OSU-HDAR12, HDAR42|
|Pharmaceutical Company||Arno Therapeutics|
|Prescription Information||Arno Therapeutics - Drug Description|
|Expectation||Change in Meningioma and Schwannoma in CNS|
|Inhibitor||HDAC - Histone deacetylase inhibitors (HDACi), pan-HDAC inhibitor|